Low muscle mass in individuals with cancer has a profound impact on quality of life and independence, and is associated with greater treatment toxicity and poorer prognosis. Exercise interventions are regularly being investigated as a means to ameliorate treatment-related adverse effects, and nutrional/supplementation strategies to augment adaptations to exercise are highly valuable. Creatine (Cr) is a naturally-occurring substance in the human body that plays a critical role in energy provision during muscle contraction. Given the beneficial effects of Cr supplementation on lean body mass, strength, and physical function in a variety of clinical populations, there is therapeutic potential in individuals with cancer at heightened risk for muscle loss. Here, we provide an overview of Cr physiology, summarize the evidence on the use of Cr supplementation in various aging/clinical populations, explore mechanisms of action, and provide perspectives on the potential therapeutic role of Cr in the exercise oncology setting.
1.Introduction
Individuals with cancer are at a high risk of skeletal muscle wasting that may be exacerbated by tumor-related factors and cancer therapies (certain hormone and chemotherapies in particular) [1] [2] [3] [4] [5] [6] [7] . An emerging body of literature supports the role of exercise as a means to ameliorate these treatment-related declines and improve clinically relevant patient outcomes [7] [8] [9] [10] . Indeed, the existing evidence is that progressive resistance training (PRT) can improve physical function, muscle strength and body composition in patients undergoing a variety of treatments [10] [11] [12] [13] [14] [15] [16] .
Nevertheless, given the implications of low muscle mass on treatment toxicity and prognosis, identifying strategies to enhance adaptations to exercise training in a cancer population are of both clinical benefit and importance [17] [18] [19] [20] . More recently, there has been an increasing appreciation for the role of nutritional and dietary supplement interventions, both alone and with exercise, to maintain or improve clinically relevant outcomes and augment training adaptations in cancer patients [21] [22] [23] [24] .
Creatine (Cr) is one of the most extensively studied supplements, with research demonstrating its efficacy to augment lean body mass (LBM) accretion, increase muscle strength, and improve physical function in a variety of healthy and clinical populations [25] . More recently, Cr supplementation has gained attention in the medical field as a result of the beneficial effects found in numerous muscular and neurological diseases, such as McArdle disease, Duchenne dystrophy, myasthenis gravis, amyotrophic lateral sclerosis, and Parkinson's disease [17, 26, 27] . Given the potent additive effects of Cr on muscle performance and LBM, it's unsurprising that Cr is now being considered as a therapeutic aid in some cancer contexts [28] . Nevertheless, supplementation with Cr in a cancer context, particularly in human participants, is notably sparse. Paucity of research in this area may stem from lack of awareness of the potential role of Cr supplementation in a cancer setting, misunderstanding of mechanisms of action, safety concerns from unfounded media reports, or a combination of the above. Thus, the purpose of this narrative review is to provide: (1) an overview of Cr physiology; (2) summarize studies investigating the therapeutic use of Cr supplementation in cancer and other clinical populations; (3) provide perspectives on the potential therapeutic role of Cr supplementation to treat cancer-related physical impairments, (4) identify specific types of cancer groups that may benefit the most from supplementation and (5) offer suggestions for future research.
2.Creatine metabolism
Cr is a naturally-occurring substance in the human body, synthesized endogenously in the kidneys, pancreas and liver at a rate of ~1-2 g/day [29] . Additionally, approximately 1 gram of Cr can be consumed by individuals with a diet high in meat and fish [30] . The majority of Cr (95%) is stored in skeletal muscle (as free creatine or phosphocreatine), with the rest found in the brain and testes [25] . Approximately 2 g/day of Cr is lost as creatinine in urine. Given that rates of excretion typically match levels of endogenous production and intake, the most efficient way to increase intramuscular Cr stores is through supplementation [30] .
Cr is a component of the high-energy phosphate, phosphocreatine (PCr), which plays a critical role in rapid energy provision during skeletal muscle contraction [21] . Re-phosphorylation of adenosine diphosphate (ADP) to adenosine triphosphate (ATP) during and following exercise ( Figure 1) is reliant on the amount of PCr stored in the muscle (PCr + ADP ↔ Cr + ATP) [25] .
In addition to its role as a temporal energy buffer, PCr acts as a spatial energy buffer to shuttle high-energy phosphates between mitochondria and cellular ATP utilization sites [31] . It is hypothesized that Cr uptake by skeletal muscle is modulated by muscle activity [32] . As PCr availability diminishes with intense exercise, ability to sustain exercise effort declines accordingly.
Further, an increase in availability of PCr may allow for accelerated resynthesis of ATP during exercise [25, 33] . In this manner, PCr content in the muscle may be an important regulator of exercise capacity. As a result, the ergogenic effects of Cr supplementation are likely an increase in intramuscular PCr [32, 34] , enhancing exercise capacity, and leading to an increase in training quality and overall training volume [25, 33] . In other words, an increase in the body's Cr stores may allow for better recovery between sets of exercises or repeated efforts, allowing the individual to perform more higher quality work and receive a better "dose" of exercise. When done consistently, this can add up to potentially greater improvements in LBM and strength compared to exercise alone.
3.Creatine supplementation in healthy aging/clinical populations
This section is not intended to be an exhaustive review of the relevant literature examining Cr supplementation in healthy aging/clinical populations. Rather, it is intended to outline the efficacy of Cr supplementation using select studies representative of the broader body of literature in improving relevant cancer-related outcomes (sarcopenia, loss of strength, bone health and physical function) that are experienced in other populations. Studies were chosen based on research design (randomised, double-blind, placebo-controlled), form of creatine used (creatine monohydrate), population being studied (clinical patients and older adults), and dependent variable reported (body composition and physical function). Indeed, more comprehensive reviews of Cr supplementation are available in healthy aging [35] [36] [37] , neurodegenerative [36, 38] and muscular disorders [39] .
3.1Healthy aging
Aging is associated with an incremental loss in muscle mass, physical function, and independence.
Additionally, intramuscular stores of creatine are ~25% lower in older [40] and middle-aged adults [41] than younger individuals. However, individuals with low intramuscular total Cr concentrations show an enhanced ability to increase creatine content following Cr supplementation [32] . Cr supplementation has been shown to increase muscle strength and function, enhance fatigue resistance, and improve performance in activities of daily living irrespective of exercise training in older populations [42, 43] . A summary of the studies discussed in this review examining Cr supplementation in healthy aging/clinical populations are presented in Table 1 .
Stout et al. [42] found significant increases in handgrip strength and physical working capacity among elderly men and women supplementing with Cr for 14 days. The significant delay in the onset of neuromuscular fatigue, as measured by the physical working capacity (PWCFT) test, may have been due to elevated muscle PCr content, which can decrease the reliance on anaerobic glycolysis, reduce intramuscular lactate and ammonia accumulation, and therefore delay fatigue. Short-term Cr supplementation has also been shown to improve upper and lower body muscular strength. Gotshalk et al. [44] reported significant increases in bench press (4.11.4 kg) and leg press (16.14.4 kg) strength, as well as significant improvements in lower body mean power and timed sit-to-stand following 7 days of Cr supplementation in older men [45] . Supporting these findings, Canete et al. [44] demonstrated a 12% improvement in timed sit-to-stand following 7 days of Cr supplementation in older women.
Cr supplementation in conjunction with PRT can result in greater adaptations in skeletal muscle as compared with PRT alone. Multiple studies have shown greater improvements in strength when Cr supplementation is combined with whole body PRT in older adults [49] [50] [51] . Results from a meta-analysis undertaken by Devries and Phillips [37] indciated that Cr supplementation during PRT enhanced the gain in LBM, strength, and functional performance over PRT alone in older adults. Similarly, Brose and colleagues [46] reported significant increases in total body mass, fatfree mass, and isometric knee extension strength following 14 weeks of whole body resistance training plus Cr supplementation. Furthermore, after a six-month randomized controlled trial, researchers reported that Cr supplementation combined with PRT significantly increased appendicular lean mass, maximal strength, and muscle function to a greater extent than PRT alone in vulnerable older adults [47] .
Cr supplementation combined with PRT also has beneficial effects on bone health. In older men, 10 weeks of Cr supplementation (0.1g/kg) combined with a structured PRT completed three times per week led to a significant reduction in bone resorption by 30% (assessed using the bone biomarker NTx), compared to a non-significant increase of 13% in the placebo group [48] . These results support previous findings from Chilibeck et al. [49] , showing Cr supplementation (0.3g/kg for 5 days, 0.07g/kg for 79 days) during 12 weeks of supervised PRT in healthy older males significantly increased upper-limb bone mineral content (BMC) by 3.2%, compared to a nonsignificant decrease in the placebo group. Given that bone turnover is a relatively slow process typically requiring 9 months to detect changes [50, 51] , these findings are somewhat remarkable.
While several studies have indicated potential benefits from Cr supplementation on bone health, others have found no effect. Lobo et al. [52] investigated the effects of long-term, low-dose Cr supplementation (1g/day) without exercise for 52 weeks on bone health in postmenopausal women and found that Cr had no greater effect on bone mineral density (BMD) or bone microarchitecture compared to placebo. Additionally, Gualano et al. [47] showed no additional benefit of Cr supplementation (20 g/day for 5 days + 5 g/day for 24 weeks) to PRT on lumbar spine, proximal femur or whole body BMD, or serum bone markers in postmenopausal women. Further, Brose et al. [50] found no effect from Cr supplementation (5g/day) on serum osteocalcin (indicator of bone formation) in healthy older men following a 14-week PRT program. As it stands, results are mixed in relation to Cr and bone health. Notably, studies employing higher volumes of resistance training (i.e. greater number of sets per muscle group per week) combined with Cr supplememtation appear to have a beneficial effect on LBM, muscle strength and physical function and bone health in older adults [37] . However, longer term studies (>12 months) with rigourous methodology utilising higher training volume with Cr are warranted. Becker muscular dystrophy [54] . Participants in the Cr group who were able to walk during the intervention saw a significant decrease in urinary excretion of cross-linked N-telopeptides of Type 
4.Musculoskeletal dysfunction in cancer
Individuals with cancer are exposed to a variety of cancer-specific factors that result in decrements in muscle mass and function, such as tumor-related factors, cancer therapies (in particular certain hormone and chemotherapies), malnutrition, physical inactivity along with increasing age and comorbidities [1] [2] [3] [4] [5] [6] . To date, the primary focus of research around muscle toxicity has been confined to cachexia. Importantly, sarcopenia is also a chief concern in this population, particularly
given the implications of decreased muscle mass and strength on the incidence and prevalence of treatment toxicity and associations with poorer prognosis in lung cancer [63] , colorectal cancer [64] , pancreatic cancer [65, 66] and renal cell carcinoma [1, 63, 67] . Sarcopenia and cachexia are somewhat distinct in their etiology, though they can be interrelated in a cancer context whereby a sarcopenic patient can become cachectic, or cachexia can exacerbate sarcopenic symptoms, further depleting already low levels of muscle mass. Regardless, reductions in muscle mass and strength are associated with profound decrements in quality of life and independence, greater toxicity from treatment and all-cause mortality. The prevalence of muscle dysfunction varies based on the type and stage of cancer, treatment received and methodology of measurement.
4.1Sarcopenia
Sarcopenia refers to the age-related loss of muscle mass and function that typically accelerates with advancing age [3] . Characterized by changes in tissue quality, decreases in satellite cells, denervation and/or atrophy of type II muscle fibers and an increase in myosteatosis (fat infiltration in skeletal muscle); sarcopenia is associated with impairments in muscle strength, physical function and may increase the risk of falls [68] [69] [70] . Sarcopenia may be of particular relevance in cancer, whereby many individuals are diagnosed at an older age, often presenting with sarcopenic characteristics at diagnosis. Prevalence of sarcopenia in different types of cancer and stages of disease has not been well defined in the oncology literature, likely compounded by lack of universal diagnostic criteria [3] . Nevertheless, prevalence of sarcopenia in individuals with cancer can range from 11-74% depending on the diagnostic criteria and methods of assessment [71] [72] [73] [74] [75] .
4.2Cachexia
Cachexia is distinct from sarcopenia in that it is a more aggressive form of muscle wasting, characterized by profound, unintentional weight loss (muscle and fat mass) that cannot be fully ameliorated with nutritional interventions [5, 76, 77] . Indeed, development of cachexia further depletes already low muscle mass, thereby exacerbating the development of sarcopenia. Criteria for diagnosis of cachexia are a topic of ongoing discussion, though such criteria include weight loss >5% in the past 6 months [76] . A discussion of the mechanisms of cachexia is beyond the scope of this review, and for further information readers are referred to reviews by Tisdale [78] and Aoyagi et al. [79] Briefly, this severe muscle wasting syndrome is thought to be a result of a combination of factors, including systemic inflammation, tumor metabolism and tumor-mediated effects, along with malnutrition and physical inactivity [76] . Cachexia is a major cause of morbidity and mortality, and management of weight loss and cachectic symptoms are of high clinical importance to minimize the impact of this syndrome [76, 80] .
4.3Body composition
Cancer treatments are also associated with poor body composition, through loss of muscle mass and/or increase in fat mass. Chemotherapy is regularly associated with increased adiposity during treatment, with some studies demonstrating significant increases in body fat percentage up to a
year following the cessation of treatment [81] [82] [83] [84] [85] [86] . Accumulation of fat mass and/or loss of muscle mass have been documented in prostate cancer patients undergoing androgen deprivation therapy (ADT) [87] [88] [89] . Moreover, the use of corticosteroids to manage cancer and treatment side effects is associated with weight gain and redistribution of body fat [90] . Indeed, Cushingoid features (truncal obesity, dorsocervical and facial adiposity) can develop within the first two months of glucocorticoid therapy [90] .
Several mechanisms for the adverse changes in body composition with cancer treatments have been proposed including lower levels of physical activity, development of menopause (in breast cancer), and treatment-related metabolic perturbations [84] . Importantly, there is increasing evidence that poor body composition and specifically, low muscle mass can increase severity of treatment toxicities [18] [19] [20] . Moreover, impairments in muscle mass can predispose individuals to a loss in physical function and the ability to perform activities of daily living, increase the risk of falls and fractures, leading to a reduction in independence and quality of life (QoL), and an increased risk of mortality [68] [69] [70] [91] [92] [93] [94] . Clearly, identification of novel strategies to maintain or improve muscle mass and strength is of high priority and clinical importance.
There is strong evidence suggesting Cr supplementation can promote the overexpression of genes and proteins related to muscle hypertrophy [95, 96] , as well as satellite cell activation [34] . Olsen et al. [34] reported that in healthy humans, Cr supplementation in combination with PRT amplified the increase in satellite cell number and myonuclei concentration in skeletal muscle fibers, thus facilitating muscle growth and hypertrophy. Cr has also been shown to enhance expression of myogenin and other myogenic regulatory factors that regulate myosin heavy chain expression, affecting the contractile protein content (actin and myosin) [97] . The growth-promoting effects of Cr may be extremely useful in situations where anabolic activity is suppressed, such as muscle wasting diseases, ageing populations, and cancer patients.
4.4Bone health
Cancer induced bone loss is indicated in the majority of cancers, with a variety of interrelated factors from dietary and physical activity patterns, loss of muscle mass, cancer cells, cancer therapies (particularly chemotherapy and hormone therapy) and metastatic disease [98, 99] . 
5.Cr supplementation in cancer patients
The few studies examining the effects of Cr in cancer patients have been mixed, with some showing no effect while others show some clinically meaningful benefit. A summary of these studies can be found in Table 2 . Jatoi et al. [28] examined Cr supplementation in 263 colorectal cancer patients experiencing "anorexia/weight loss syndrome". In this trial, incurable patients were randomly assigned to either Cr (20g/day load x 5 days followed by 2 g/day) or placebo powder with identical dosing. Body weight was assessed weekly for one month and thereafter monthly while the patient remained on Cr or placebo. Appetite, QoL, and grip strength were also assessed.
The primary endpoint was the percentage of patients who gained 10% of their baseline weight by 1 month. Out of 263 patients, only 3 gained 10% of their baseline weight over 1 month: two in the Cr group, and one in the placebo group. No significant differences in any of the measured variables were observed between the two groups. One possible explanation for lack of significant findings is the absence of a training stimulus. It is hypothesized that Cr uptake by skeletal muscle is modulated by muscle activity. [32] Muscle inactivity may contribute to a decrease in Cr uptake, and therefore compromise the effect of Cr supplementation on body weight and strength. individuals. [119] The clinical implications of these reductions in muscle strength and physical function in individuals with cancer are of critical importance, as those with lower levels of physical function are more likely to experience premature mortality than those with higher physical function. [92] [93] [94] Galvao et al. [120] proposed a theoretical model of the role of PRT to improve musculoskeletal fitness, resulting in an increase in physical reserve capacity in men treated with ADT. Here, we propose that Cr supplementation in addition to PRT may provide even more improvements in musculoskeletal fitness, results in a greater increase in physical reserve capacity While the physiological mechanisms linking Cr supplementation to an increase in exercise
performance are yet to be fully elucidated, one possibility is an increase in PCr content in Type II muscle fibers. PCr content is 5-15% higher in Type II than Type I fibers. [121, 122] Additionally, the rate of PCr degradation is faster in Type II than Type I fibers during high-intensity, short duration activities. [121] Conversely, Type I fibers resynthesise PCr at a faster rate than Type II fibers during recovery periods. After Cr supplementation, both fiber types increase total and PCr content, with a trend toward a larger increase in Type II fibers. [123] Type II muscle fibers are associated with higher anaerobic ATP turnover rate and peak power output during exercise.
Evidence suggests that fatigue during intense muscle contraction may be attributable to the utilization of PCr, specifically in Type II muscle fibers. [124] Therefore, any mechanism capable of increasing intramuscular Cr stores may help to prevent PCr depletion, and delay fatigue, during intense exercise.
Earlier work by Harris et al. [32] showed increases in skeletal muscle Cr content by 20-50%
following Cr supplementation, with 20% of the increase in Cr accounted for by increases in PCr.
Although it is unclear whether or not cancer patients experience a significant decrease in PCr stores, there is evidence in clinical populations with muscle atrophy demonstrating depletion of intramuscular stores of PCr in Type II muscle fibers. [125] Therefore, while further research is needed in individuals with cancer, results from other clinical populations and muscle wasting diseases suggest it is plausible that Cr supplementation may have beneficial effects on muscle function and performance in this patient population.
7.Which cancer groups are most likely to benefit from Cr supplementation
The heterogeneity of cancer type, treatments, definitions of sarcopenia and cachexia, along with methods of assessment, makes it difficult to accurately define the prevalence of muscle wasting in cancer. Pamoukdjian et al. [72] Certainly, given the results of studies in healthy aging and other clinical populations, any individual with cancer engaging in resistance training stands to benefit from Cr supplementation.
Nevertheless, there may be subsets of cancer types, or treatments that may see greater benefit with Cr supplementation. Indeed, the highest prevalence of weight loss and cachexia has been observed in head and neck, pancreatic, lung, colorectal and gastric cancer. [3, 127] Older adults may be particularly vulnerable to muscle loss and could potentially benefit from Cr supplementation.
Additionally, those undergoing certain treatments such ADT for prostate cancer are at a higher risk for muscle loss indicating the potential utility of Cr supplementation.
8.Safety considerations
Despite the expansive research supporting Cr as a safe and highly effective nutritional supplement in healthy aging and individuals with neurological/muscle disorders, [25, 33] it remains largely misunderstood, with unsubstantiated claims of side effects such as kidney and liver damage and dehydration. Contrary to these claims, Cr supplementation has not been associated with any signs of renal impairment. [25, 33, 128] Indeed, the safety of Cr supplementation on kidney function as measured by glomerular filtration rate has been demonstrated in a variety of apparently healthy and clinical populations. [129] [130] [131] [132] In fact, Cr supplementation is being considered as a means to improve musculoskeletal and neurological functioning in patients with chronic kidney disease. [27] Long-term Cr supplementation has been investigated in other clinical populations such as
Parkinson's disease and Huntington's disease, in studies ranging from 2-5 years, and doses up to 10g/day, with no adverse effects of supplementation or impact on renal dysfunction reported. [133] [134] [135] Further, studies of Cr supplementation have reported no adverse effects on hydration status or muscle cramps. Researchers have conducted a meta-analysis and reported no evidence of altered hydration status or thermoregulation following Cr supplementation. [136] Additionally, Greenwood et al [137] found no increase in dehydration, cramping, and/or muscle injury rates among college football players following long-term (3 years) Cr supplementation. Cr is one of the most rigorously studied supplements to date, with hundreds of studies demonstrating safety, tolerability, and wide ranging health and performance benefits. [25, 33] Moreover, there is no compelling evidence that short-or long-term Cr supplementation has any detrimental effects on kidney function, gastrointestinal distress, muscle dysfunction or hydration status. [25, 33, [129] [130] [131] [132] It should be noted however, that given the paucity of research examining Cr supplementation in patients with cancer, studies examining the safety and tolerability of Cr in a cancer context, in particular interactions with treatments such as radiation therapy, chemotherapy, steroid therapy and immunotherapy, are necessary.
9.Conclusions and future directions
Given the beneficial effects of Cr supplementation on muscle mass, strength, BMD and physical function in a variety of clinical populations, the therapeutic potential for application in cancer is substantial. Indeed, randomized controlled trials are beginning to emerge, investigating the effects of Cr supplementation to attenuate cancer-related weight loss. [28] Nevertheless, application in various cancer contexts is still largely theoretical, with research in this area remaining sparse.
Consequently, additional RCT's are needed in this area to fully understand the impact of supplementation on clinically-meaningful outcomes in individuals with cancer, in particular those at a higher risk of muscle wasting, such as head and neck, pancreatic, and gastrointestinal cancers.
The majority of studies in this area have examined Cr supplementation in isolation on clinical outcomes in individuals with cancer. Importantly, the beneficial effects of Cr supplementation are more likely a result of an increase in intramuscular Cr stores allowing an individual to get a greater "dose" of exercise, which can accumulate over time, leading to greater adaptations to exercise training (such as muscle mass, strength and physical function), than of the supplement alone.
Accordingly, we recommend that future studies examine the effects of Cr supplementation in conjunction with resistance exercise on important clinical outcomes in individuals with cancer at a heightened risk of muscle loss (as mentioned above), such as muscle mass, strength and physical function. Additionally, experiments in vitro or with animals are warranted to determine the mechanisms of effects of Cr to treat skeletal muscle toxicity in individuals with cancer.
Collectively, further research in this area will allow for a greater understanding of the therapeutic effects of Cr supplementation in this patient population.
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